NASDAQ · Biotechnology

ADMA Biologics Inc (ADMA) Stock

$10.33 +1.87% NASDAQ: ADMA Healthcare

Valuation

MetricValue
Price$10.33
Market Cap$2.39B
P/E Ratio14.08
P/B Ratio5.67
P/S Ratio4.59
EPS (TTM)$0.60
52-Week High$20.46
52-Week Low$7.21
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE39.59%
ROA24.69%
ROCE35.58%
Gross Margin61.27%
Operating Margin40.57%
Net Margin32.98%
Debt/Equity0.50
Current Ratio6.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$81.0M$154.0M$258.0M$426.0M$510.0M
Operating Profit$-58.0M$-39.0M$22.0M$139.0M$191.0M
Net Profit$-72.0M$-66.0M$-28.0M$198.0M$147.0M
EPS$-0.61$-0.43$-0.13$0.81$0.60
Op Margin-72.1%-25.6%8.4%32.6%37.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$276.0M$348.0M$329.0M$489.0M$624.0M
Total Liabilities$135.0M$196.0M$194.0M$140.0M$147.0M
Cash$51.0M$87.0M$51.0M$103.0M$88.0M
Borrowings$103.0M$154.0M$141.0M$82.0M$80.0M

Latest News

ADMA Biologics (ADMA) Faces Class Actions And Probes Over Revenue Allegations Simply Wall St. · Jul 15, 2026 ADMA Biologics (ADMA) Stock Looks Undervalued Even After A 5 Year Run Simply Wall St. · Jul 15, 2026 ADMA: Lowering target price to $8.00 Argus Research · Jul 15, 2026 Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights Zacks · Jul 13, 2026 Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views? Zacks · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-112.0M$-60.0M$9.0M$119.0M$50.0M
Investing Cash Flow$-27.0M$-28.0M$-10.0M$-17.0M$-44.0M
Financing Cash Flow$0$-8.0M$-15.0M$-6.0M$-44.0M
Net Cash Flow$-5.0M$35.0M$-35.0M$52.0M$-16.0M
Free Cash Flow$-126.0M$-73.0M$4.0M$110.0M$28.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.82
EV / EBITDA10.29
FCF Yield4.96%
Quick Ratio3.81
Interest Coverage24.53
Return 1Y-52.03%
Return 3Y121.18%
Return 5Y412.42%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABUSArbutus Biopharma Corporation $4.18 -2.56% 5.63 $825.71M 0.00%
GRFSGrifols, S.A. $7.27 -0.27% 14.60 $6.15B 1.24%
IVVDInvivyd, Inc. $0.70 -3.87% -2.08 $206.34M 0.00%

About ADMA Biologics Inc

ADMA Biologics Inc (ADMA) stock trades at $10.33 with a market capitalization of $2.39B. The stock is valued at a price-to-earnings (P/E) ratio of 14.08, price-to-book of 5.67, price-to-sales of 4.59. Over the past 52 weeks the stock has ranged between $7.21 and $20.46, and currently trades 49.5% below its 52-week high.

On profitability, ADMA Biologics Inc generates a return on equity (ROE) of 39.59% — well above the market average, a sign of a high-quality business, return on capital employed of 35.58%, an operating margin of 40.57%, a net profit margin of 32.98%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides